BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 9, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 7, 2017
View Archived Issues
CARB-X grant supports Vedanta's development of human microbiome drug candidate VE-303
Read More
Takeda recaps highlights of second quarter of fiscal 2017
Read More
NousCom raises series B financing to advance neoantigen-based cancer vaccines
Read More
Krystal Biotech receives equity-based award to support epidermolysis bullosa work
Read More
Preclinical evaluation of first-in-class nucleic acid therapeutic RCT-201
Read More
Novel BTK inhibitor PRN-2246 demonstrates efficacy in multiple sclerosis model
Read More
AT-527 well tolerated and reduces HCV RNA in phase Ia trial
Read More
Cancer-targeted theranostic probe [177Lu]DOTA-NIR-790 effective in vivo
Read More
Study with pramlintide supports theoretical basis for Alzheimer's disease treatment
Read More
Klotho Therapeutics announces series A financing to advance patent pending version of Klotho
Read More
Patient dosing begins in ORION-11 study of inclisiran
Read More
FDA approves Zelboraf for Erdheim-Chester disease
Read More
NanoCarrier obtains license to VB-111 in Japan
Read More
Ionis submits NDA to FDA for inotersen for hereditary TTR amyloidosis
Read More
New study launched under collaborative Alzheimer's Prevention Initiative Generation program
Read More
FDA lifts clinical hold on phase I trials of UCART-123
Read More
AnaptysBio reports topline phase I results for ANB-019
Read More
Wave Life Sciences commences phase I study of WVE-210201 for DMD
Read More
FDA approves Alecensa for ALK+ metastatic NSCLC
Read More
Eutilex enters immuno-oncology partnership with Zhejiang Huahai Pharmaceutical
Read More
Bristol-Myers Squibb presents ROM-K channel blockers for hypertension
Read More
Stealth BioTherapeutics begins MMPOWER-3 phase III study of elamipretide
Read More
Boehringer Ingelheim discloses orexin OX1 receptor antagonists
Read More
